Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05654870 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
A Phase 3 study, sponsored by Neurocrine Biosciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT05654870 is a Phase 3 study that was terminated before completion, run by Neurocrine Biosciences. The registered enrollment target is 8 participants.
The verdict
NCT05654870, a Phase 3 study, was terminated before completion, sponsored by Neurocrine Biosciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Interventions
- DRUG Placebo
- DRUG Valbenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-01-05 |
| Est. Completion | 2023-11-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05654870
The ClinicalTrials.gov registry entry for NCT05654870 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05654870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05654870 about?
NCT05654870 is a clinical study titled "Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia". This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
What is the current status of trial NCT05654870?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2023-01-05. Estimated completion is 2023-11-08.
What interventions are being tested in trial NCT05654870?
The interventions under investigation include: Placebo (DRUG), Valbenazine (DRUG).
Who is sponsoring clinical trial NCT05654870?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.